Markets & Investing
Chinese developer Midea Real Estate seeks up to US$493m in Hong Kong float
It is offering 180 million shares priced at $17 to $21.50 apiece.
Chinese developer Midea Real Estate seeks up to US$493m in Hong Kong float
It is offering 180 million shares priced at $17 to $21.50 apiece.
Rattled consumers beef up savings amidst growing uncertainties
The number of residents pledging to save spare cash rose from 68% to 72% in Q2.
Metal producer Shandong Gold raises $4.82b in IPO priced at low end
The firm sold 327.7 million shares priced at $14.70 apiece.
HKEX eyes tech acquisitions in growth strategy shift mimicking Nasdaq
Takeovers in data, analytics and blockchain rank high in the agenda.
Hot pot chain Haidilao defies market slump after raising nearly US$1b in IPO
The firm sold around 8% of equity capital at $17.80 per share.
The Asian Export Awards 2018 welcomes MICCI as partner
MICCI intends to be the premier advocate for the business community in Malaysia.
Meituan Dianping raises US$4.2b in IPO priced at high end
The Chinese food review firm sold 480.27 million shares at $69 apiece.
Hot pot chain Haidilao seeks ambitious US$10b valuation that towers over its peers
It’s aiming for a market cap greater than all Hong Kong-listed restaurant operators combined.
Meituan Dianping's January-April losses nearly triples ahead of mega IPO
The company booked $26.2b loss in the first four months of 2018.
Chinese movie ticketing platform seeks up to US$1b in Hong Kong IPO
Maoyan Weiying is planning to use the proceeds for R&D and product enhancements.
Has Meituan lured Tencent to its mega US$4b IPO?
The Chinese tech titan is said to be buying US$400m of stock.
Crypto mining firms test their sustainability in Hong Kong IPOs
Bitmain, Canaan and Ebang’s flotations will determine the sustainability of their tech.
Alibaba-backed e-parenting firm eyes $1b Hong Kong IPO
Babytree is targeting a valuation of up to US$5b.
Goldman-backed heart valve startup eyes Hong Kong IPO
Venus MedTech is said to be aiming to raise up to US$500m.
Hong Kong's first pre-profit biotech float Ascletis closes flat on debut
It sold 224 million shares with an IPO priced at the middle end.
China Tower raises US$6.9b in another lacklustre debut
It sold 43.1 billion shares after pricing its IPO at the low end.
Cancer drug developer seeks $7b in secondary Hong Kong listing
BeiGene is offering 65.6 million shares at $94.9 to $111.6 apiece.
Read Here
Advertise
Sign Up
